ReviewCancers2021
Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 174 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
174 citing papers in PubMed, 3 syntheses or guidelines pooled it, 260 citations in OpenAlex.
- Association of tumor-infiltrating lymphocytes with clinical outcomes in patients with triple-negative breast cancer receiving neoadjuvant chemotherapy: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Pooled it
- Detection of breast cancer lesions using APT weighted MRI: a systematic review.Journal of translational medicine · 2025Pooled it
- The Prognostic Importance of Ki-67 in Gastrointestinal Carcinomas: A Meta-analysis and Multi-omics Approach.Journal of gastrointestinal cancer · 2024Pooled it
- Efficacy and safety of neoadjuvant treatment of trastuzumab and pyrotinib plus dalpiciclib in HR-negative/HER2-positive breast cancer: an exploratory, open-label phase II study.International journal of surgery (London, England) · 2026Trial
- Computational reactive-diffusive modeling for stratification and prognosis determination of patients with breast cancer receiving Olaparib.Scientific reports · 2023Trial
- Ki-67 expression and rates of pathologic complete response in T1cN0M0 triple-negative breast cancer: a national cancer database analysis.Breast cancer research and treatment · 2026Article
- Immunohistochemical assessment of vimentin expression and Ki-67 proliferation index in conventional urothelial carcinoma: a study of 60 Egyptian patients.International urology and nephrology · 2026Article
- Article
- Predicting ki-67 expression in breast cancer via transformer and multiple instance learning on DCE-MRI.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- The Predictive Value of the Tumor-Stroma Ratio for Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive Breast Cancer.International journal of cancer · 2026Article
- Article
- Emerging biomarkers in breast fibroadenoma: implications for differential diagnosis, malignant transformation, and precision medicine.Molecular biology reports · 2026Review
- Real-world study of treatment patterns and outcomes in patients with HR+ breast cancer after progression on CDK4/6 inhibitor therapy.Lancet regional health. Americas · 2026Article
- Evaluation of plasma kynurenine 3-monooxygenase and Ki-67 as screening biomarkers for neoplasia in dogs.Journal of veterinary internal medicine · 2026Article
- Ki67 Gene Expression is Associated with Immune Cell Infiltration and Neoadjuvant Chemotherapy Response in ER+/HER2- Breast Cancer.Annals of surgical oncology · 2026Article
- Preoperative prediction of Ki-67 expression and prognosis in breast cancer based on contrast-enhanced cone-beam breast CT: a two-centre study.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- PRMT5 as a Key Driver of Stemness and Metastatic Potential in Triple-Negative Breast Cancer.Biomolecules · 2026Review
- Article
- Evaluating the Performance of Large Language Models for Breast Cancer Patient Education: A Comparative Study.Journal of cancer education : the official journal of the American Association for Cancer Education · 2026Article
- The prognostic predictive value of monocyte to high-density lipoprotein cholesterol ratio in HR+/HER- breast cancer patients.Translational cancer research · 2026Article
114 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
The advent of molecular medicine has transformed breast cancer management. Breast cancer is now recognised as a heterogenous disease with varied morphology, molecular features, tumour behaviour, and response to therapeutic strategies. These parameters are underpinned by a combination of genomic and immunohistochemical tumour factors, with estrogen receptor (ER) status, progesterone receptor (PgR) status, human epidermal growth factor receptor-2 (HER2) status, Ki-67 proliferation indices, and multigene panels all playing a contributive role in the substratification, prognostication and personalization of treatment modalities for each case. The expression of Ki-67 is strongly linked to tumour cell proliferation and growth and is routinely evaluated as a proliferation marker. This review will discuss the clinical utility, current pitfalls, and promising strategies to augment Ki-67 proliferation indices in future breast oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.